FDA approvals to watch for in 2020 | MDLinx
The FDA has granted the drug priority review, with an expected decision date in the second quarter of 2020. Dextromethorphan/bupropion for depression The FDA granted breakthrough therapy designation to AXS-05 (dextromethorphan/bupropion modulated delivery tablet, Axsome) for the treatment of major depressive disorder (MDD), as well as fast track designation for treatment-resistant depression ...
Get Price